Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Acquired by PEAK6 Investments LLC

PEAK6 Investments LLC boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 15.4% during the third quarter, HoldingsChannel reports. The fund owned 15,000 shares of the company’s stock after buying an additional 2,000 shares during the period. PEAK6 Investments LLC’s holdings in Kymera Therapeutics were worth $710,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in KYMR. Values First Advisors Inc. acquired a new position in shares of Kymera Therapeutics in the 3rd quarter valued at $61,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in Kymera Therapeutics by 27.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after buying an additional 504 shares during the period. Comerica Bank lifted its position in Kymera Therapeutics by 13.7% in the first quarter. Comerica Bank now owns 3,324 shares of the company’s stock valued at $134,000 after buying an additional 400 shares during the last quarter. Public Employees Retirement Association of Colorado acquired a new stake in shares of Kymera Therapeutics during the second quarter valued at about $139,000. Finally, Virtu Financial LLC purchased a new stake in shares of Kymera Therapeutics in the 1st quarter valued at approximately $207,000.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KYMR. Stephens began coverage on shares of Kymera Therapeutics in a research report on Monday, November 18th. They set an “overweight” rating and a $65.00 price objective for the company. UBS Group dropped their price objective on Kymera Therapeutics from $80.00 to $74.00 and set a “buy” rating for the company in a research note on Monday, November 4th. Leerink Partnrs raised Kymera Therapeutics to a “strong-buy” rating in a research note on Monday, September 9th. Morgan Stanley lifted their target price on Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 6th. Finally, Oppenheimer increased their price target on shares of Kymera Therapeutics from $52.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, September 27th. Three research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $53.40.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Pamela Esposito sold 13,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The transaction was disclosed in a filing with the SEC, which is available at this link. 15.82% of the stock is currently owned by insiders.

Kymera Therapeutics Stock Down 1.7 %

KYMR stock opened at $46.91 on Wednesday. The business has a 50 day moving average price of $46.66 and a 200 day moving average price of $42.43. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -20.05 and a beta of 2.16. Kymera Therapeutics, Inc. has a fifty-two week low of $20.32 and a fifty-two week high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, October 31st. The company reported ($0.82) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.01. Kymera Therapeutics had a negative net margin of 191.26% and a negative return on equity of 24.96%. The business had revenue of $3.74 million during the quarter, compared to the consensus estimate of $10.34 million. During the same quarter in the previous year, the firm earned ($0.90) EPS. The company’s revenue was down 20.9% compared to the same quarter last year. As a group, sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -2.79 EPS for the current year.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.